Without frequent viral load monitoring dolutegravir-based regimens not the best choice for African youth on failing ART
HIV outcomes for transgender women improved by addressing social and structural issues
'Mystery shoppers' in Kenyan pharmacies highlight issues with distribution of HIV self-tests
Fostemsavir salvage therapy continues to look good at 96 weeks
Dolutegravir dual therapy works well for both first line and maintenance treatment
Dapivirine vaginal ring effective and acceptable with longer use
Does Descovy have a role as PrEP in people who struggle with adherence?
Policing practices are consistently associated with HIV and risk behaviours among people who inject drugs
First trial results of new immune-modulating drugs presented in Mexico City
